Risk factors for bleeding during treatment with dabigatran or rivaroxaban in patients with atrial fibrillation

Trial Profile

Risk factors for bleeding during treatment with dabigatran or rivaroxaban in patients with atrial fibrillation

Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Oct 2015

At a glance

  • Drugs Dabigatran etexilate (Primary) ; Rivaroxaban (Primary)
  • Indications Stroke
  • Focus Adverse reactions
  • Most Recent Events

    • 30 Oct 2015 New trial record
    • 02 Sep 2015 Results presented at ESC Congress 2015: Annual Congress of the European Society of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top